Enterprise Value
12.2M
Cash
34.24M
Avg Qtr Burn
-16.46M
Short % of Float
2.05%
Insider Ownership
0.86%
Institutional Own.
29.93%
Qtr Updated
09/30/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AGTC-401 Details Genetic disorder, Achromatopsia, Solid tumor/s, Cancer | Failed Discontinued | |
AGTC-501 Details Genetic disorder, X-linked retinitis pigmentosa, Vision loss | Failed Discontinued | |
AGTC-402 Details Genetic disorder, Achromatopsia, Multiple myeloma | Failed Discontinued |